These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7727795)

  • 1. Synergistic antiplatelet action of nitric oxide (NO) with PGD2 and its metabolite PGJ2--relevance for cerebral circulation?
    Rodrigues M; Fitscha P; Sinzinger H
    J Physiol Pharmacol; 1994 Dec; 45(4):533-9. PubMed ID: 7727795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
    Porta C; Maiolo A; Tua A; Grignani G
    Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
    Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
    Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.
    Mardla V; Kobzar G; Samel N
    Platelets; 2004 Aug; 15(5):319-24. PubMed ID: 15370103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of some antineoplastic drugs (vincristine, doxorubicin and epirubicin) on human platelet aggregation.
    Matera C; Falzarano C; Vacca C; Falciani M; Rossi F
    J Med; 1994; 25(1-2):2-16. PubMed ID: 7930957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prostaglandin D2, 15-deoxy-Delta12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats.
    Almishri W; Cossette C; Rokach J; Martin JG; Hamid Q; Powell WS
    J Pharmacol Exp Ther; 2005 Apr; 313(1):64-9. PubMed ID: 15590767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.
    Bertelé V; Roncaglioni MC; Donati MB; de Gaetano G
    Thromb Haemost; 1983 Apr; 49(2):81-3. PubMed ID: 6346573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of prostaglandin D2 by murine mast cells: importance of metabolite formation for antiproliferative activity.
    Haberl C; Hültner L; Flügel A; Falk M; Geuenich S; Wilmanns W; Denzlinger C
    Mediators Inflamm; 1998; 7(2):79-84. PubMed ID: 9836493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic actions of prostacyclin and an isoquinoline derivative (CH-102) on ADP-induced aggregation of dog platelets in vitro.
    Pataricza J; Bor P; Szekeres L
    Biomed Biochim Acta; 1984; 43(12):1365-9. PubMed ID: 6398698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of release and role of adenosine diphosphate and thromboxane A2 during collagen-induced aggregation of platelets from cattle with Chediak-Higashi syndrome.
    Honda N; Ohnishi K; Fujishiro T; Ikeda M; Ito K
    Am J Vet Res; 2007 Dec; 68(12):1399-406. PubMed ID: 18052747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292).
    Chiba T; Ueki S; Ito W; Kato H; Takeda M; Kayaba H; Furue M; Chihara J
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():77-82. PubMed ID: 19494510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP.
    Hardy E; Glenn J; Heptinstall S; Rubin PC; Horn EH
    Thromb Haemost; 1995 Oct; 74(4):1132-7. PubMed ID: 8560425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of cisplatin and cisplatinum (II)phosphonate complex on ADP-induced platelet aggregation in vitro.
    Kostka B; Ochocki J
    Pharmazie; 1996 Dec; 51(12):990-2. PubMed ID: 8985988
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of ADP-induced human platelet aggregation by a new class of soluble guanylate cyclase activators capable of nitric oxide generation.
    Severina IS; Belushkina NN; Grigoryev NB
    Biochem Mol Biol Int; 1994 Aug; 33(5):957-67. PubMed ID: 7987264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers.
    Gries A; Herr A; Motsch J; Holzmann A; Weimann J; Taut F; Erbe N; Bode C; Martin E
    Thromb Haemost; 2000 Feb; 83(2):309-15. PubMed ID: 10739391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
    Desmond JC; Mountford JC; Drayson MT; Walker EA; Hewison M; Ride JP; Luong QT; Hayden RE; Vanin EF; Bunce CM
    Cancer Res; 2003 Jan; 63(2):505-12. PubMed ID: 12543809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.